Stay updated on Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Sign up to get notified when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.

Latest updates to the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe clinical trial record for the nintedanib study is available with its study details, results-related information, participating locations, and supporting documents. It also includes information about individual participant data sharing.SummaryDifference82%

- Check20 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide banner announces NIH website changes and links to transition updates and FAQs, noting that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.1 to v3.7.2. The study page continues to display a 403 error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe 403 error block was removed, allowing the page to display the study details rather than an error page.SummaryDifference0.5%

Stay in the know with updates to Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Effect of Nintedanib on ECM Biomarkers in IPF Clinical Trial page.